<PRE>
[Federal Register: March 23, 2001 (Volume 66, Number 57)]
[Notices]               
[Page 16277]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr23mr01-122]                         

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

 
Prospective Grant of Co-Exclusive License: Treating Inflammatory 
Bowel Disease Using Antibodies Against Interleukin-Twelve (IL-12)

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 
Part 404.7(a)(1)(i), announces that the National Institutes of Health, 
Department of Health and Human Services, is contemplating the grant of 
a co-exclusive license to practice the inventions embodied in U.S. 
Patent 5,853,697 entitled, ``Methods of Treating Established Colitis 
Using Antibodies Against IL-12,'' which was filed on October 25, 1995 
and issued on December 29, 1998, and corresponding foreign patent 
applications, to Centocor, Inc. which is located in Malvern, PA. The 
patent rights in these inventions have been assigned to the United 
States of America.
    The prospective co-exclusive license territory will be worldwide 
and the field of use will be therapeutics for the treatment of 
inflammatory bowel disease, including but not necessarily limited to 
colitis and Crohn=s disease.

DATES: Only written comments and/or license applications which are 
received by the National Institutes of Health on or before May 22, 2001 
will be considered.

ADDRESSES: Requests for copies of the patent and/or patent 
applications, inquiries, comments and other materials relating to the 
contemplated co-exclusive license should be directed to: Richard U. 
Rodriguez, M.B.A., Technology Licensing Specialist, Office of 
Technology Transfer, National Institutes of Health, 6011 Executive 
Boulevard, Suite 325, Rockville, MD 20852-3804. Telephone: (301) 496-
7056, X287; Facsimile: (301) 402-0220; E-mail: <A HREF="mailto:rodrigur@od.nih.gov">rodrigur@od.nih.gov</A>.

SUPPLEMENTARY INFORMATION: The technology claimed in the aforementioned 
patent and patent applications relates to methods of treating 
inflammatory bowel diseases through the administration of antibodies 
against IL-12. A method for evaluating the effectiveness of the IL-12 
antibodies in reducing the inflammatory response is also claimed.
    The prospective co-exclusive license will be royalty-bearing and 
will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 
Part 404.7. The prospective co-exclusive license may be granted unless 
within sixty (60) days from the date of this published notice, the NIH 
receives written evidence and argument that establish that the grant of 
the license would not be consistent with the requirements of 35 U.S.C. 
209 and 37 CFR Part 404.7. This notice serves to modify the previous 
intent to grant notice published in the Federal Register, 62 FR 13162, 
March 19, 1997.
    Applications for a license in the field of use filed in response to 
this notice will be treated as objections to the grant of the 
contemplated co-exclusive license. Comments and objections submitted to 
this notice will not be made available for public inspection and, to 
the extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.

    Dated: March 16, 2001.
Jack Spiegel,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer.
[FR Doc. 01-7225 Filed 3-22-01; 8:45 am]
BILLING CODE 4140-01-P

</PRE>